Paradigm in the news

 
Paradigm Careers
08.06.15

Paradigm and TME Research To Launch Precision Medicine Breast Cancer Registry

Registry is designed to determine clinical impact of molecular profiling on breast cancer patients being treated in the neoadjuvant setting [ANN ARBOR, MI and Allentown, PA, August 06, 2015]– Paradigm and TME Research today announced the launch of a precision medicine breast cancer registry. The Paradigm Neoadjuvant Breast Registry will use Paradigm’s PCDx next generation […]

Read more
 
 
Paradigm Careers
07.15.15

Paradigm Signs Contract With Stratose for Personalized Medicine Service

Will Help Provide Paradigm Cancer Diagnostic (PCDx™) to Oncologists and Large Member Base ANN ARBOR, Mich. and PHOENIX, July 15, 2015 /PRNewswire-USNewswire/ — Paradigm, a molecular information & Next Generation Sequencing corporation specializing in providing cancer testing for patients with cancer, today announced that it has entered into a contractual agreement with Stratose for coverage […]

Read more
 
 
Paradigm Careers
06.18.15

Paradigm Announces Partnership with Cure Forward to Power Novel Social Data Platform

Relationship designed to accelerate patient enrollment in targeted oncology clinical trials and delivery of precision medicine [CAMBRIDGE, MA and ANN ARBOR, MI Thursday, June 18, 2015]– Paradigm and Cure Forward today announced a partnership under which Paradigm will serve as a core diagnostic laboratory partner (DLP) for the provision of Next-Generation Sequencing (NGS)-based molecular profiling […]

Read more
 
 
Paradigm Careers
04.28.15

Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study

Analysis of next-generation sequencing (NGS)-based platforms suggests potential benefits of novel NGS platform for cancer patients. [PHOENIX, AZ and ANN ARBOR, April 28, 2015] —Data from a small cohort published OncoTargets and Therapy today shows that the Paradigm Cancer Diagnostic Test (PCDx) performed better than Foundation Medicine’s FoundationOne test across a number of key clinical […]

Read more
 
 
Paradigm Careers
04.20.15

Paradigm and TD2 Announce Strategic Partnership For Tumor Profiling Service

Collaboration to provide expanded use of Paradigm Cancer Diagnostic (PCDx™) service by oncologists across large oncology network [SCOTTSDALE, AZ and ANN ARBOR, MI Monday, April 20, 2015]– Paradigm and Translational Drug Development (TD2) today announced a partnership under which Paradigm will provide their PCDx test to TD2’s affiliated oncology provider networks. PCDx is a Next-Generation […]

Read more
 
 
Paradigm Careers
02.03.15

Paradigm Announces Enhancement to PCDx Cancer Testing Service

Addition of Protein Biomarkers, Including Key Immune Targets PD-L1 and PD1, Further Augments Tests Ability to Personalize Cancer Therapy [PHOENIX, AZ and ANN ARBOR, MI February 3, 2015]– Paradigm today announced an expansion to their Next Generation Paradigm Cancer Diagnostic (PCDx) service with the addition of key protein biomarkers analyzed by immunohistochemistry (IHC). This enhancement […]

Read more
 
 
Paradigm Careers
08.20.14

Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc.

Collaboration will enhance clinical trials by identifying proteomic and other predictors of response to targeted cancer therapies. Ann Arbor, MI and Phoenix AZ, August 20, 2014 Paradigm, a non-profit corporation established to bring cutting-edge next-generation sequencing and proteomic diagnostics and biomarker driven clinical trials to cancer patients, today announced a collaboration with TESARO, Inc. Paradigm […]

Read more
 
 
Paradigm Careers
08.12.14

Forma Therapeutics and Paradigm Announce Molecular Profiling Collaboration for Drug Candidates

Strategic partnership to characterize genomic predictors of response for FORMA’s preclinical cancer therapies, accelerating clinical decision making ANN ARBOR, Mich. and WATERTOWN, Mass. August 12, 2014 – Paradigm and FORMA Therapeutics, Inc. announced today a multi-year partnership to identify predictive response markers and measure pharmacodynamic activity for two of FORMA’s advanced preclinical candidates. Working with […]

Read more
 
 
Paradigm Careers
08.05.14

Paradigm Initiates Genomic Profiling for Pharmatech’s AccessPPM Cancer Registry Program

Novel clinical trial matching protocol enables greater access to genomic profiling and targeted clinical studies for cancer patients nationwide. ANN ARBOR, Mich. and DENVER, Aug. 5, 2014 /PRNewswire-USNewswire/ Paradigm has announced today they have initiated genomic testing for Pharmatech’s AccessPPM Cancer Registry. Pharmatech’s AccessPPM is a cancer registry designed to collect EMR data and genomic […]

Read more
 
 
Paradigm Careers
07.09.14

Comprehensive molecular profiling of lung adenocarcinoma

Nature Published July 9, 2014 Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen […]

Read more
 

Start getting better results, faster.

Order PCDx